

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF T
02 FEB 15

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name Abbott Laboratories			
2. Address <input type="checkbox"/> Check if different than previously reported 1710 Rhode Island Ave., N.W., Suite 300 . Washington, DC 20036			
3. Principal Place of Business (if different from line 2) City: Abbott Park State/Zip (or Country) Illinois 60064			
4. Contact Name	Telephone	E-mail (optional)	5. Senate ID #
Cynthia B. Sensibaugh	(202) 659-8524	cynthia.sensibaugh@abbott.com	66-
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID #
Self			3000

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) OR Year End (July 1-Dece

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____ 11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000

\$10,000 or more ⇨ \$ _____
Income (nearest \$20,000)

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000

\$10,000 or more ⇨ \$ 1,460,000.00
Expenses (nearest \$20,000)

14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of


Method A. Reporting amounts using LDA definiti

Method B. Reporting amounts under section 6033 Internal Revenue Code

Method C. Reporting amounts under section 162 Internal Revenue Code

Signature

Printed Name and Title _____



EO-2 (REV. 6/98)

PA

Registrant Name Abbott Laboratories Client Name Self

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City

State/Zip (or Country)

22. New general description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

Francis X. Tirrell

ISSUE UPDATE

24. General lobbying issues previously reported that no longer pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Open to client

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, affiliated organization

Signature _____ Date _____

Printed Name and Title _____

Form LD-2 (Rev. 6/98)

Page 2

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

- 1. H.R. 2330, S. 1191 - Agriculture Appropriations FY 2002, funding for Women, Infants and Children program.
- 2. H.R. 3061, S. 1536 - Labor, HHS Appropriations FY 2002, funding for state AIDS Drug Assistance programs under the Ryan White Act.

17. House(s) of Congress and Federal agencies contacted Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

- 1. H.R. 2330, S. 1191 - Agriculture Appropriations FY 2002, amendment concerning reimportation of prescription drugs
- 2. H.R. 526, S. 1052 - Patients' Bill of Rights
- 3. H.R. 2887, H.R. 3452, S. 838, S. 1789 - Best Pharmaceuticals for Children Act
- 4. FDA review, inspection and enforcement activities

17. House(s) of Congress and Federal agencies contacted Check if None

House
Senate
Food and Drug Administration
Health and Human Services - Office of the Secretary

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Cynthia B. Sensibaugh	
Rosemary T. Haas	
Francis X. Tirrell	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code and information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

- 1. H.R. 1624, S. 913 - Access to Cancer Therapies Act of 2001
- 2. S. 357 - Medicare Preservation and Improvement Act of 2001
- 3. S. 358 - Medicare Prescription Drug and Modernization Act of 2001
- 4. H.R. 1089, S. 554 - Access to Innovation for Medicare Patients Act of 2001
- 5. H.R. 1798, S. 1066 - Medicare Patient Access Preventive and Diagnostic Tests Act
- 6. H.R. 2768, H.R. 3046, H.R. 3391 - Medicare Regulatory and Contracting Reform Act of 2001, provision relating to methods for determining payment basis for new lab tests
- 7. Medicare coverage of anti-obesity drugs

17. House(s) of Congress and Federal agencies contacted Check if None

House
Senate
Health and Human Services - Office of the Secretary
Centers for Medicare and Medicaid Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Cynthia B. Sensibaugh	
Rosemary T. Haas	
Francis X. Tirrell	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code. Information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (cont) (one per page)

16. Specific lobbying issues

- 8. Medical local medical review policies in South Carolina, Florida and Pennsylvania to reduce reimbursement for vitamin D therapy
- 9. H.R. 3061, S. 1536 - Labor, HHS Appropriations FY 2002, amendment expanding entities eligible for favorable government pricing
- 10. Ensure adequate Medicare reimbursement for new technologies to increase the safety of the blood supply

17. House(s) of Congress and Federal agencies contacted Check if None

House
Senate
Health and Human Services - Office of the Secretary
Centers for Medicare and Medicaid Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Cynthia B. Sensibaugh	
Rosemary T. Haas	
Francis X. Tirrell	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

Form LD-2 (Rev. 6/98)

Page 6

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant is engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific lobbying issues

1. H.R. 2550 - Economic Revitalization Tax Act of 2001

17. House(s) of Congress and Federal agencies contacted Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date _____

Printed Name and Title _____

Form LD-2 (Rev. 6/98)

Page 7

Registrant Name Abbott Laboratories Client Name Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each cot information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific lobbying issues

1. H.R. 1786, S. 847 - To impose tariffs on certain casein and milk protein concentrates

17. House(s) of Congress and Federal agencies contacted Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Mark E. Barmak	
Elaine R. Leavenworth	
Rosemary T. Haas	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Cynthia B. Sensibaugh Date 2/15/02

Printed Name and Title Cynthia B. Sensibaugh - Director, Federal Government Affairs

